Missing Script

Get updates

MS-N181 · Acupuncture plus behavioral sleep care · Appraised October 30, 2026

Electroacupuncture added to CBT-I during gynecologic-cancer chemotherapy

Aliases: EA plus CBT-I

Evidence at a glance

  • Question: Does electroacupuncture add sleep and anxiety benefit to cognitive behavioral therapy for insomnia during gynecologic-cancer chemotherapy?
  • Finding: A 76-participant sham-controlled trial reported a larger four-week improvement in sleep quality when electroacupuncture was added to CBT-I. The study was single-center, short and unable to blind practitioners.
  • Evidence label: Positive short-term randomized signal
  • Benefit: The between-group PSQI change exceeded the study’s prespecified reference threshold, with parallel insomnia and anxiety improvements.
  • Certainty: Low to moderate. The sham comparator and complete short-term follow-up strengthen the result, but replication and longer follow-up are needed.
  • Risk: No serious adverse events were reported. Minor-event reporting was limited, and acupuncture during chemotherapy requires infection and bleeding precautions.
  • Cancer-control boundary: The trial measured sleep and anxiety, not tumor response, treatment efficacy, recurrence or survival.

Study details

  • Intervention: All participants received weekly CBT-I for four weeks. The active arm also received 12 electroacupuncture sessions: three per week, 30 minutes, 2 Hz, typically 1–4 mA at GV20, GV24, EX-HN3 and HT7.
  • Comparator: Blunt nonpenetrating sham needles with disconnected leads at the same locations, plus identical CBT-I.
  • Population: Adults aged 20–70 with gynecologic malignancies, insomnia and anxiety while receiving chemotherapy.
  • Design and sample: Single-center randomized, outcome-assessor-blinded trial; 76 randomized, 38 per group, with all completing four weeks.
  • Primary outcome: Modified Pittsburgh Sleep Quality Index at week four.
  • Results: Change in PSQI favored active electroacupuncture by −3.11 points (95% CI −4.11 to −2.11; P<.001). AIS remission threshold was reached by 71.1% versus 42.1%; HAMA ≤14 by 92.1% versus 65.8%.
  • Negative and uncertain findings: The PSQI omitted its medication component; sleep-stage estimates came from a consumer wearable not validated for cancer populations; durability beyond four weeks is unknown.
  • Funding and conflicts: Shanghai Municipal Health Commission Traditional Chinese Medicine Research Project 2022QN023; authors declared no conflicts.

Practical safety context

Needling should be cleared with the oncology team when neutropenia, thrombocytopenia, anticoagulation, skin infection, lymphedema risk or implanted devices are relevant. This regimen should not be reproduced without trained practitioners and chemotherapy-specific precautions.

Questions for the care team

  • Are my blood counts and infection risk suitable for acupuncture today?
  • Is standard CBT-I available without adding needling?
  • How will sleep benefit be assessed beyond four weeks?

Primary sources

Last literature search: October 30, 2026 · Record appraisal: October 30, 2026

Educational evidence summary, not medical advice. Do not change cancer treatment or supportive medications without discussing the decision with the treating team.